NorthWest Biotherapeutics Inc (NWBO)

[Basin Street Blues]

Innate Pharma Slumps; AstraZeneca Ends a Monolizumab Study (1)
By Leonard Kehnscherper and Phil Serafino
(Bloomberg) -- (Updates with stock decline in first paragraph.)
Innate Pharma fell as much as 22% after AstraZeneca ended a study of the company’s monalizumab in head and neck cancer, saying an early analysis indicated the medicine wasn’t effective.
Stock declines 17% to EU2.52 at 9:12 a.m. in Paris, extending YTD drop to 43%
Interim analysis of the Interlink-1 Phase 3 study sponsored by AstraZeneca didn’t meet a threshold for efficacy, according to a statement
AstraZeneca informed Innate the study will be discontinued
“We remain confident in the development program for monalizumab in lung cancer, where encouraging data has been previously reported,” said Mondher Mahjoubi, CEO of Innate Pharma